KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $825.9 million.

  • Supernus Pharmaceuticals' Non-Current Assets rose 1752.74% to $825.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 540.88%. This contributed to the annual value of $682.0 million for FY2024, which is 1307.19% down from last year.
  • Supernus Pharmaceuticals' Non-Current Assets amounted to $825.9 million in Q3 2025, which was up 1752.74% from $643.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Non-Current Assets high stood at $1.1 billion for Q4 2021, and its period low was $643.5 million during Q2 2025.
  • Moreover, its 5-year median value for Non-Current Assets was $869.6 million (2023), whereas its average is $861.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Non-Current Assets surged by 4560.58% in 2021 and then tumbled by 1898.03% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Non-Current Assets (Quarter) stood at $1.1 billion in 2021, then dropped by 10.96% to $968.4 million in 2022, then decreased by 18.98% to $784.6 million in 2023, then fell by 13.07% to $682.0 million in 2024, then grew by 21.09% to $825.9 million in 2025.
  • Its Non-Current Assets was $825.9 million in Q3 2025, compared to $643.5 million in Q2 2025 and $659.7 million in Q1 2025.